David A. Karanian

1.5k total citations
22 papers, 1.2k citations indexed

About

David A. Karanian is a scholar working on Cellular and Molecular Neuroscience, Pharmacology and Cognitive Neuroscience. According to data from OpenAlex, David A. Karanian has authored 22 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Cellular and Molecular Neuroscience, 11 papers in Pharmacology and 5 papers in Cognitive Neuroscience. Recurrent topics in David A. Karanian's work include Neuroscience and Neuropharmacology Research (12 papers), Cannabis and Cannabinoid Research (11 papers) and Neurotransmitter Receptor Influence on Behavior (7 papers). David A. Karanian is often cited by papers focused on Neuroscience and Neuropharmacology Research (12 papers), Cannabis and Cannabinoid Research (11 papers) and Neurotransmitter Receptor Influence on Behavior (7 papers). David A. Karanian collaborates with scholars based in United States, South Africa and Germany. David A. Karanian's co-authors include Ben A. Bahr, David W. Self, Alexandros Makriyannis, Queenie B. Brown, Eric F. Schmidt, Christina A. Schad, Michael A. Sutton, Ryan K. Bachtell, JodiAnne T. Wood and Kwang-Ho Choi and has published in prestigious journals such as Nature, Nature Communications and Journal of Neuroscience.

In The Last Decade

David A. Karanian

22 papers receiving 1.2k citations

Peers

David A. Karanian
Brian C. Shonesy United States
M. Reibaud France
Guo-Zhang Jin China
Carmen Mazzola Italy
Leyre Urigüen Spain
Jian-Ping Gong China
Sharon Goodenough Germany
Jean-Paul Terranova France
Bihua Bie United States
Guo-Hua Bi United States
Brian C. Shonesy United States
David A. Karanian
Citations per year, relative to David A. Karanian David A. Karanian (= 1×) peers Brian C. Shonesy

Countries citing papers authored by David A. Karanian

Since Specialization
Citations

This map shows the geographic impact of David A. Karanian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David A. Karanian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David A. Karanian more than expected).

Fields of papers citing papers by David A. Karanian

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David A. Karanian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David A. Karanian. The network helps show where David A. Karanian may publish in the future.

Co-authorship network of co-authors of David A. Karanian

This figure shows the co-authorship network connecting the top 25 collaborators of David A. Karanian. A scholar is included among the top collaborators of David A. Karanian based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David A. Karanian. David A. Karanian is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Stepan, Antonia F., Tuan P. Tran, Christopher J. Helal, et al.. (2018). Late-Stage Microsomal Oxidation Reduces Drug–Drug Interaction and Identifies Phosphodiesterase 2A Inhibitor PF-06815189. ACS Medicinal Chemistry Letters. 9(2). 68–72. 25 indexed citations
2.
Naidoo, Vinogran, Spyros P. Nikas, Vidyanand G. Shukla, et al.. (2017). Inhibitor of Endocannabinoid Deactivation Protects Against In Vitro and In Vivo Neurotoxic Effects of Paraoxon. Journal of Molecular Neuroscience. 63(1). 115–122. 10 indexed citations
3.
Zuhl, Andrea M., Charles E. Nolan, Michael A. Brodney, et al.. (2016). Chemoproteomic profiling reveals that cathepsin D off-target activity drives ocular toxicity of β-secretase inhibitors. Nature Communications. 7(1). 13042–13042. 59 indexed citations
4.
Naidoo, Vinogran, David A. Karanian, Subramanian K. Vadivel, et al.. (2012). Equipotent Inhibition of Fatty Acid Amide Hydrolase and Monoacylglycerol Lipase – Dual Targets of the Endocannabinoid System to Protect against Seizure Pathology. Neurotherapeutics. 9(4). 801–813. 49 indexed citations
5.
Naidoo, Vinogran, Spyros P. Nikas, David A. Karanian, et al.. (2010). A New Generation Fatty Acid Amide Hydrolase Inhibitor Protects Against Kainate-Induced Excitotoxicity. Journal of Molecular Neuroscience. 43(3). 493–502. 42 indexed citations
6.
Kosten, Therese A., David A. Karanian, Colin N. Haile, et al.. (2007). Memory impairments and hippocampal modifications in adult rats with neonatal isolation stress experience. Neurobiology of Learning and Memory. 88(2). 167–176. 45 indexed citations
7.
Butler, David, Jennifer Bendiske, Mary L. Michaelis, David A. Karanian, & Ben A. Bahr. (2007). Microtubule-stabilizing agent prevents protein accumulation-induced loss of synaptic markers. European Journal of Pharmacology. 562(1-2). 20–27. 52 indexed citations
8.
Williams, John S., JodiAnne T. Wood, Lakshmipathi Pandarinathan, et al.. (2007). Quantitative Method for the Profiling of the Endocannabinoid Metabolome by LC-Atmospheric Pressure Chemical Ionization-MS. Analytical Chemistry. 79(15). 5582–5593. 70 indexed citations
9.
Karanian, David A., JodiAnne T. Wood, John S. Williams, et al.. (2007). Endocannabinoid Enhancement Protects against Kainic Acid-Induced Seizures and Associated Brain Damage. Journal of Pharmacology and Experimental Therapeutics. 322(3). 1059–1066. 77 indexed citations
10.
Karanian, David A., Spyros P. Nikas, JodiAnne T. Wood, et al.. (2007). Enhancement of endogenous cannabinoid responses through FAAH inhibition provides cellular and functional protection against excitotoxic brain damage.. The FASEB Journal. 21(6). 1 indexed citations
11.
Karanian, David A., David Butler, Alexandros Makriyannis, & Ben A. Bahr. (2006). A Reversible FAAH Inhibitor Exhibits Efficient Bioavailability While Enhancing Neuroprotective Endocannabinoid Responses. The FASEB Journal. 20(5). 1 indexed citations
12.
Karanian, David A., et al.. (2006). 3-Nitropropionic acid toxicity in hippocampus: Protection throughN-methyl-D-aspartate receptor antagonism. Hippocampus. 16(10). 834–842. 32 indexed citations
13.
Bahr, Ben A., David A. Karanian, Sagar S Makanji, & Alexandros Makriyannis. (2006). Targeting the endocannabinoid system in treating brain disorders. Expert Opinion on Investigational Drugs. 15(4). 351–365. 46 indexed citations
14.
Butler, David, et al.. (2005). Cellular Responses to Protein Accumulation Involve Autophagy and Lysosomal Enzyme Activation. Rejuvenation Research. 8(4). 227–237. 40 indexed citations
15.
Karanian, David A., Queenie B. Brown, Alexandros Makriyannis, Therese A. Kosten, & Ben A. Bahr. (2005). Dual Modulation of Endocannabinoid Transport and Fatty Acid Amide Hydrolase Protects against Excitotoxicity. Journal of Neuroscience. 25(34). 7813–7820. 104 indexed citations
16.
Karanian, David A., Queenie B. Brown, Alexandros Makriyannis, & Ben A. Bahr. (2005). Blocking cannabinoid activation of FAK and ERK1/2 compromises synaptic integrity in hippocampus. European Journal of Pharmacology. 508(1-3). 47–56. 45 indexed citations
17.
18.
Sutton, Michael A., Eric F. Schmidt, Kwang-Ho Choi, et al.. (2003). Extinction-induced upregulation in AMPA receptors reduces cocaine-seeking behaviour. Nature. 421(6918). 70–75. 277 indexed citations
19.
Schmidt, Eric F., Michael A. Sutton, Christina A. Schad, et al.. (2001). Extinction Training Regulates Tyrosine Hydroxylase during Withdrawal from Cocaine Self-Administration. Journal of Neuroscience. 21(7). RC137–RC137. 51 indexed citations
20.
Self, David W., et al.. (2000). Effects of the Novel D1Dopamine Receptor Agonist ABT‐431 on Cocaine Self‐Administration and Reinstatement. Annals of the New York Academy of Sciences. 909(1). 133–144. 43 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Brian C. Shonesy Breakdown of academic impact, for papers by M. Reibaud Breakdown of academic impact, for papers by Guo-Zhang Jin Breakdown of academic impact, for papers by Carmen Mazzola Breakdown of academic impact, for papers by Leyre Urigüen Breakdown of academic impact, for papers by Jian-Ping Gong Breakdown of academic impact, for papers by Sharon Goodenough Breakdown of academic impact, for papers by Jean-Paul Terranova Breakdown of academic impact, for papers by Bihua Bie Breakdown of academic impact, for papers by Guo-Hua Bi
Rankless by CCL
2026